Rabbit monoclonal antibody: potential application in cancer therapy.

By targeting antigens specifically, monoclonal antibodies represent a new class of therapeutic agents for the clinical management of various diseases including cancers. Monoclonal antibody technology has been greatly developed by reducing murine content in antibodies to minimize side effects in clinical applications. However, several intrinsic disadvantages of antibodies with murine origin limit the clinical efficacy of monoclonal antibodies based targeted therapy. The development of rabbit monoclonal antibody technology provides an alternative source of monoclonal antibodies with higher specificity and less cost for the development of routine targeted therapy against cancers.

[1]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[2]  T. Raybould,et al.  Production of stable rabbit-mouse hybridomas that secrete rabbit mAb of defined specificity. , 1988, Science.

[3]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[4]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[5]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[6]  R. Mage,et al.  Gene conversion and hypermutation during diversification of VH sequences in developing splenic germinal centers of immunized rabbits. , 1999, Journal of immunology.

[7]  R. Dillman,et al.  Monoclonal antibodies in cancer therapy: 25 years of progress. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[9]  L. Old,et al.  Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. , 2001, Cancer research.

[10]  J. Bystryn,et al.  Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. , 1982, Hybridoma.

[11]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[12]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[13]  K L Knight,et al.  Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Knight,et al.  Generating the antibody repertoire in rabbit. , 1994, Advances in immunology.

[15]  S. Scott,et al.  Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. , 1998, Cancer practice.

[16]  T. Grogan,et al.  A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Markus,et al.  OKT3 in the reversal of acute hepatic allograft rejection. , 1987, Transplantation proceedings.

[19]  A. Lockhart,et al.  Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab , 2009, OncoTargets and therapy.

[20]  A. D. Dei Tos,et al.  Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. , 2005, American journal of clinical pathology.

[21]  D. Gerber,et al.  Targeted therapies: a new generation of cancer treatments. , 2008, American family physician.

[22]  Zhiqiang An,et al.  [Therapeutic monoclonal antibodies]. , 2009, Revue medicale de Liege.

[23]  Jungang Chen,et al.  A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models , 2010, PloS one.

[24]  N. Kemeny,et al.  Phase I study of anticolon cancer humanized antibody A33. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Aarden,et al.  A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. , 2010, Journal of immunological methods.